Dr Andrew Brockway, PhD, GAICD
Chief Executive Officer, Non-Executive Board Director
Andrew has over twenty years pharmaceutical and research experience, including leading development and oversight of global programs, including sponsored and collaborative research trials, paediatric and adult studies, and biologicals and pharmaceutical experience. He has held strategic & leadership roles in pharma (local and global), clinical research organization (CRO), and phase 1 units.
Andrew has significant experience in vaccine clinical research within industry, including global pharma roles (based in Europe) leading worldwide operational teams for diseases of developing world portfolio (malaria, tuberculosis and HIV vaccine development). He has experience working with external and philanthropic organisations to progress development of novel medicines.
Additionally, Andrew has been Head of Business Development ANZ, for a global CRO. In this role he led new business growth, strategic partnerships, and combining R&D and commercial delivery.
He is also Board Director for fara (Friedreich Ataxia Research Association), a not-for-profit patient advocacy organization that supports research into treatments and a cure for Friedreich Ataxia.